Results 51 to 60 of about 12,272 (191)
British Journal of Clinical Pharmacology, EarlyView.Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu +7 more
wiley +1 more source
PCSK9 inhibitors – past, present and future [PDF]
Expert Opinion on Drug Metabolism & Toxicology, 2015 Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular disease (CVD) morbidity and mortality. Statins are the treatment of choice for lowering LDL-C but a considerable number of patients treated with statins are unable to achieve LDL-C target values and many are statin-intolerant.
openaire +2 more sources
Chemistry – A European Journal, EarlyView.Hybrid macrocyclic peptides unite genetically encoded peptide libraries with the structural complexity of synthetic small molecules. This Review critically analyzes phage‐compatible cyclization and diversification chemistries, highlights emerging opportunities beyond traditional cysteine‐based approaches, and outlines how future advances may enable the
Titia Rixt Oppewal, Clemens Mayer
wiley +1 more source
PCSK9 peptide inhibitors [PDF]
Science-Business eXchange, 2014 Although many companies are chasing inhibitors of PCSK9 for lowering LDL cholesterol, antibodies or siRNAs that require injection are dominating the field. Roche's Genentech unit and a joint team from Pfizer and the University of Queensland are betting that peptides might provide an oral competitor.
openaire +1 more source
Food Biomacromolecules, EarlyView.Abstract Cardiovascular diseases (CVDs) remain the leading cause of global mortality, necessitating effective preventive and adjunct therapeutic strategies beyond conventional pharmacological interventions. Although previous reviews have focused on individual nutrients or dietary patterns, this review provides a mechanism‐based, integrative perspective
Sridevi Shanmugam +7 more
wiley +1 more source
TRIM31–LOX‐1 Axis: A Novel Therapeutic Frontier in Atherosclerosis
iNew Medicine, EarlyView.ABSTRACT Atherosclerosis, driven by a vicious cycle of lipid accumulation and chronic inflammation, underlies most cardiovascular diseases. Macrophages exacerbate this process by internalizing oxidized low‐density lipoprotein (oxLDL), forming foam cells, and releasing inflammatory mediators. A recent study published in Circulation identified the TRIM31–
Qian Zhang, Cheng Xue Qin
wiley +1 more source
Metrnl: A Novel Therapeutic Target in Atherosclerosis
iNew Medicine, EarlyView.ABSTRACT Atherosclerosis is a chronic inflammatory vascular disease and the main pathological basis of cardiovascular and cerebrovascular events. Exploration of endogenous protective factors in the disease is beneficial for the establishment of new therapeutic strategies.
Pin Wang, Dao‐Xin Wang, Chao‐Yu Miao
wiley +1 more source
BMC Cardiovascular DisordersBackground High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months.
Kaveh Hosseini +6 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground The clinical benefits of early PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor use in patients with acute large vessel occlusion undergoing endovascular therapy (EVT) remain unclear.
Tong Wu +9 more
doaj +1 more source
Application of PCSK9 Inhibitors in Practice [PDF]
Circulation Research, 2017 Although the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and development of therapeutic antagonists represent a major triumph of modern clinical medicine, efforts to implement PCSK9 inhibitors (PCSK9i) in patient care have been sobering.
Tina M, Kaufman +5 more
openaire +2 more sources